Navigation Links
China Jo-Jo Drugstores, Inc. Receives Delisting Notice from NASDAQ
Date:5/10/2013

HANGZHOU, China, May 10, 2013 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (the "Company"), a retail and wholesale distributor of pharmaceutical and other healthcare products in China, today announced that on May 9, 2013, it was notified by The NASDAQ Stock Market LLC ("NASDAQ"), notifying it of its failure to maintain a minimum closing bid price of $1.00 over the then preceding 30 consecutive trading days for its common stock as required by NASDAQ Listing Rule 5550(a)(2).  The Company has until November 5, 2013, to regain compliance.

The Company intends to actively monitor the bid price for its common stock between now and November 5, 2013, and will consider available options to resolve the deficiency and regain compliance with the minimum bid price requirement.

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its subsidiaries and contractually controlled affiliates, is a retailer and wholesale distributor of pharmaceutical and other healthcare products in the People's Republic of China. As of March 31, 2013, the Company has 52 retail pharmacies throughout Zhejiang Province and Shanghai.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.


'/>"/>
SOURCE China Jo-Jo Drugstores, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
2. The World Market for Dialysis Equipment and Services (United States, Japan, UK, Italy, India, China, Australia and Canada )
3. China Biologic Reports Financial Results for the First Quarter of 2013
4. China Botanic Pharmaceutical Inc. Announces Receipt of Delisting Notice
5. CPhI China 2013 Increases Customer Content Services and Expands Thanks to a Double Digit Pharma Industry Growth Rate and a Burgeoning Generics Market
6. Patent Issued In China For EntreMeds Lead Drug Candidate ENMD-2076
7. China Biologic Products to Report First Quarter 2013 Financial Results
8. Thorne Research and YouCare Pharmaceutical Group Announce Joint Venture Deal to Market Nutritional Supplements in China
9. China Nepstar Chain Drugstore Filed 2012 Annual Report on Form 20-F
10. MEDTEC China 2013: The Leading Medical Device Manufacturing Event in Asia Moves to a New Level
11. China Biologics Shandong Taibang Subsidiary Donates Lifesaving Plasma Products for the Injured in the Yaan Earthquake
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies ... with the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice ... distribution and sales network, direct the efforts of the surgical sales teams, manage ...
Breaking Medicine News(10 mins):